M. Vintilă *, Monica Băluță **, V. Vintilă ***
* Conf. Dr. Marius Vintilă, Catedra de Medicină Internă, șeful Secției Cardiologie, Spitalul Colentina
** Dr. Monica Băluță, asistent universitar, medic specialist, Catedra de Medicină Internă, Spitalul Colentina, Secția Cardiologie
*** Dr. Vlad Vintilă, medic rezident, Spitalul Universitar de Urgență București
Abstract
The therapeutic approach in hypertrophic cardiomyopathy is aimed at improving symptoms and exerci se capacity and at preventing complication, especially sudden death which is the leading cause of mortality. The primary treatment option for prevention of sudden death is Amiodarone, with or without an implanted defibrillator. For slowing the disease progression and symptoms control! the most commonly used agents are beta blockers, non-dihydropyridine calcium chanel blockers and some antiar -rhythmics. Surgical left ventricular myotomy-myectomy may be indicated to reduce the obstruction and the symptoms. Recently, new non-pharmacological and non-surgical methods such as septal ablation and pacing and alcohol induced septal infarction are available. There is a hope that gene therapy could resolve at least partly this disease, but such treatments have not yet developed, although some progress has been made.